Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Quantech (QQQQ) -- Ignore unavailable to you. Want to Upgrade?

To: Daniel Miller who wrote (328)	1/28/1999 6:51:00 PM
From: r laird	Read Replies (1) \| Respond to of 338

there is news on yahoo! cannot get into site,must be down. just type in qqqq for stock quote. message will show up. will try to drop news. not sure it will work! 01/27 18:31 Quantech seeks market clearance for pregnancy test ST. PAUL, Minn., Jan 27 (Reuters) - Quantech Ltd <QQQQ.OB>. said Wednesday it is seeking approval from the U.S. Food and Drug Administration to market a rapid pregnancy test. The Quantech pregnancy test measures the levels of human chorionic gonadotropin (hCG), a hormone secreted by a fertilized egg that is detectable in maternal serum 8 to 10 days after fertilization. The company said the test is regarded as the most definitive diagnostic marker for determining pregnancy. Quantitative hCG tests are also used to diagnose ectopic pregnancy, a leading cause of abdominal pain for women. Pending system clearance, the beta-hCG test will be available on Quantech's DBx rapid diagnostic system. "Every woman of child-bearing age cared for in the emergency room and given X-rays, medications or procedures that could injure a fetus typically are tested for beta-hCG," said Robert Case, chief executive officer of Quantech. "Rapid, on-site beta-hCG tests will prevent lengthy waits for results from the hospital lab and allow physicians to begin treatment promptly." Quantech said it is completing commercial development of the DBx system, which will be able to analyze whole blood or urine in less than 20 minutes and perform a wide range of tests commonly ordered in emergency rooms. The first tests scheduled to be available on the system will be the quantitative HCG (pregnancy detection) test, a cardiac panel (CK-MB, troponin I and myoglobin), a white and red blood cell count panel, a coagulation panel and an amylase (pancreatic function) test. ((--Chicago Equities News at 312 408 8787, chicago.equities.newsroom@reuters.co